Morgan Stanley maintains Vir Biotech at 'equalweight' with a price target of $15.00

  • Investing.com
Morgan Stanley maintains Vir Biotech at 'equalweight' with a price target of $15.00

An analyst from Morgan Stanley maintained Vir Biotech (NASDAQ: VIR ) at 'equalweight' with a price target of $15.00 from a prior price target of %currency%%price%.

Prior to this rating, Vir Biotech had 8 buy ratings, 1 hold ratings, and 0 sell ratings.

For consensus analyst estimates and price targets on Vir Biotech, click here. For more news on Vir Biotech, click here.

Vir Biotech's stock price closed at $23.05. They are down -7.47% in the last month and down -57.36% in the last 12 months.

According to Investing Pro, Vir Biotech's fair value is $24.39, an upside of 5.83%. Vir Biotech's fair value comes with a medium degree of uncertainty, according to InvestingPro.

Check out Vir Biotech's recent earnings performance and financials here.

Drop an image here or Supported formats: *.jpg, *.png, *.gif up to 5mb

Error: File type not supported

Drop an image here or

100

Related Articles